{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:11:13Z","timestamp":1784121073696,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.taap.2026.117924","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T23:28:53Z","timestamp":1782257333000},"page":"117924","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Improving biomarker robustness for in silico cardiac safety assessment through an excitation-contraction coupling model"],"prefix":"10.1016","volume":"514","author":[{"given":"Ulfa Latifa","family":"Hanum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Ikhsanul","family":"Qauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ariyadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Moo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2026.117924_bb0005","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1517\/14740338.4.3.509","article-title":"ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis","volume":"4","author":"Cavero","year":"2005","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.taap.2026.117924_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2017.00917","article-title":"Uncertainty quantification reveals the importance of data variability and experimental design considerations for in silico Proarrhythmia risk assessment","volume":"8","author":"Chang","year":"2017","journal-title":"Front. Physiol."},{"key":"10.1016\/j.taap.2026.117924_bb0015","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.vascn.2016.03.009","article-title":"An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel","volume":"81","author":"Crumb","year":"2016","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.taap.2026.117924_bb0020","article-title":"Optimization of an in silico cardiac cell model for proarrhythmia risk assessment","volume":"8","author":"Dutta","year":"2017","journal-title":"Front. Physiol."},{"key":"10.1016\/j.taap.2026.117924_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2023.1266084","article-title":"Machine learning approach to evaluate TdP risk of drugs using cardiac electrophysiological model including inter-individual variability","volume":"14","author":"Fuadah","year":"2023","journal-title":"Front. Physiol."},{"key":"10.1016\/j.taap.2026.117924_bb0030","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1002\/psp4.13229","article-title":"A stacking ensemble machine learning model for evaluating cardiac toxicity of drugs based on in silico biomarkers","volume":"13","author":"Fuadah","year":"2024","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.taap.2026.117924_bb0035","doi-asserted-by":"crossref","DOI":"10.1145\/3539801","article-title":"Enabling new flexibility in the SUNDIALS suite of nonlinear and differential\/algebraic equation solvers","volume":"48","author":"Gardner","year":"2022","journal-title":"ACM Trans. Math. Softw."},{"key":"10.1016\/j.taap.2026.117924_bb0040","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1161\/CIRCRESAHA.111.253955","article-title":"Human atrial action potential and Ca2+ model","volume":"109","author":"Grandi","year":"2011","journal-title":"Circ. Res."},{"key":"10.1016\/j.taap.2026.117924_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2020.106890","article-title":"A general procedure to select calibration drugs for lab-specific validation and calibration of proarrhythmia risk prediction models: an illustrative example using the CiPA model","volume":"105","author":"Han","year":"2020","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.taap.2026.117924_bb0050","doi-asserted-by":"crossref","DOI":"10.1007\/s00204-025-04079-z","article-title":"Validation of new AI-based classification method for in silico cardiac safety assessment of drugs following the CiPA framework","author":"Hanum","year":"2025","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.taap.2026.117924_bb0055","article-title":"Drug induced TdP risks classification assay using electro-mechanical models of human ventricle based on CiPA framework","author":"Heikhmakhtiar","year":"2025","journal-title":"Toxicol. Res."},{"key":"10.1016\/j.taap.2026.117924_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11020406","article-title":"Application of convolutional neural networks using action potential shape for in-silico proarrhythmic risk assessment","volume":"11","author":"Jeong","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.taap.2026.117924_bb0065","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1038\/s41598-020-62344-w","article-title":"Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cells","volume":"10","author":"Kramer","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.taap.2026.117924_bb0070","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.yjmcc.2017.03.008","article-title":"A model of cardiac contraction based on novel measurements of tension development in human cardiomyocytes","volume":"106","author":"Land","year":"2017","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.taap.2026.117924_bb0075","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.116.004628","article-title":"Improving the In Silico assessment of proarrhythmia risk by combining hERG (Human Ether-\u00e0-go-go-Related Gene) channel\u2013drug binding kinetics and multichannel pharmacology","volume":"10","author":"Li","year":"2017","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"10.1016\/j.taap.2026.117924_bb0080","article-title":"General principles for the validation of Proarrhythmia risk prediction models: an extension of the CiPA in silico strategy","volume":"107","author":"Li","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2026.117924_bb0085","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/cpt.1184","article-title":"Assessment of an in silico mechanistic model for Proarrhythmia risk prediction under the CiPA initiative","volume":"105","author":"Li","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2026.117924_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmpb.2022.106934","article-title":"Considering population variability of electrophysiological models improves the in silico assessment of drug-induced torsadogenic risk","volume":"221","author":"Llopis-Lorente","year":"2022","journal-title":"Comput. Methods Prog. Biomed."},{"key":"10.1016\/j.taap.2026.117924_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2024.1374355","article-title":"Evaluation of cardiac pro-arrhythmic risks using the artificial neural network with ToR-ORd in silico model output","volume":"15","author":"Mahardika","year":"2024","journal-title":"Front. Physiol."},{"key":"10.1016\/j.taap.2026.117924_bb0100","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.pbiomolbio.2020.06.007","article-title":"In-silico human electro-mechanical ventricular modelling and simulation for drug-induced pro-arrhythmia and inotropic risk assessment","volume":"159","author":"Margara","year":"2021","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"10.1016\/j.taap.2026.117924_bb0105","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/cvr\/cvr044","article-title":"Simulation of multiple ion channel block provides improved early prediction of compounds\u2019 clinical torsadogenic risk","volume":"91","author":"Mirams","year":"2011","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.taap.2026.117924_bb0110","article-title":"Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation","volume":"7","author":"O\u2019Hara","year":"2011","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.taap.2026.117924_bb0115","doi-asserted-by":"crossref","first-page":"24045","DOI":"10.1038\/s41598-024-71169-w","article-title":"Explainable artificial intelligence (XAI) to find optimal in-silico biomarkers for cardiac drug toxicity evaluation","volume":"14","author":"Pramudito","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.taap.2026.117924_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmpb.2025.108609","article-title":"Elevating performance and interpretability of in silico classifiers for drug proarrhythmia risk evaluations using multi-biomarker approach with ranking algorithm","volume":"261","author":"Qauli","year":"2025","journal-title":"Comput. Methods Prog. Biomed."},{"key":"10.1016\/j.taap.2026.117924_bb0125","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development","volume":"58","author":"Redfern","year":"2003","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.taap.2026.117924_bb0130","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/009286150503900407","article-title":"ICH E14: a new regulatory guidance on the clinical evaluation of QT\/QTc internal prolongation and proarrhythmic potential for non-antiarrhythmic drugs","volume":"39","author":"Sager","year":"2005","journal-title":"Drug Inf. J. (DIJ)."},{"key":"10.1016\/j.taap.2026.117924_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2013.11.004","article-title":"Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the cardiac safety research consortium","author":"Sager","year":"2014","journal-title":"Am. Heart J."},{"key":"10.1016\/j.taap.2026.117924_bb0140","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/cpt.2137","article-title":"Translational models and tools to reduce clinical trials and improve regulatory decision making for QTc and Proarrhythmia risk (ICH E14\/S7B updates)","volume":"109","author":"Strauss","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2026.117924_bb0145","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.48890","article-title":"Development, calibration, and validation of a novel human ventricular myocyte model in health, disease, and drug block","volume":"8","author":"Tomek","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.taap.2026.117924_bb0150","article-title":"ToR-ORd-dynCl: an update of the ToR-ORd model of human ventricular cardiomyocyte with dynamic intracellular chloride","author":"Tomek","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.taap.2026.117924_bb0155","article-title":"Mechanistic model-informed proarrhythmic risk assessment of drugs: review of the \u201cCiPA\u201d initiative and design of a prospective clinical validation study","volume":"103","author":"Vicente","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2026.117924_bb0160","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/cpt.1303","article-title":"Assessment of multi-Ion Channel block in a phase I randomized study design: results of the Ci <scp>PA<\/scp> phase I <scp>ECG<\/scp> biomarker validation study","volume":"105","author":"Vicente","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2026.117924_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.761691","article-title":"Assessment of drug Proarrhythmicity using artificial neural networks with in silico deterministic model outputs","volume":"12","author":"Yoo","year":"2021","journal-title":"Front. Physiol."},{"key":"10.1016\/j.taap.2026.117924_bb0170","article-title":"A multiscale computational model of cardiac electrophysiology for drug-induced pro-arrhythmic risk stratification","author":"Yuniarti","year":"2025","journal-title":"Biomed. Eng. Lett."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X26002206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X26002206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:01:48Z","timestamp":1784120508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X26002206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":34,"alternative-id":["S0041008X26002206"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2026.117924","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving biomarker robustness for in silico cardiac safety assessment through an excitation-contraction coupling model","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2026.117924","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117924"}}